menu search

GLUE / How Much Upside is Left in Monte Rosa Therapeutics (GLUE)? Wall Street Analysts Think 226.46%

How Much Upside is Left in Monte Rosa Therapeutics (GLUE)? Wall Street Analysts Think 226.46%
The mean of analysts' price targets for Monte Rosa Therapeutics (GLUE) points to a 226.5% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock. Read More
Posted: Jan 25 2023, 11:18
Author Name: Zacks Investment Research
Views: 110879

GLUE News  

Down -56.34% in 4 Weeks, Here's Why You Should You Buy the Dip in Monte Rosa Therapeutics (GLUE)

By Zacks Investment Research
October 24, 2023

Down -56.34% in 4 Weeks, Here's Why You Should You Buy the Dip in Monte Rosa Therapeutics (GLUE)

Monte Rosa Therapeutics (GLUE) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combi more_horizontal

How Much Upside is Left in Monte Rosa Therapeutics (GLUE)? Wall Street Analysts Think 226.46%

By Zacks Investment Research
January 25, 2023

How Much Upside is Left in Monte Rosa Therapeutics (GLUE)? Wall Street Analysts Think 226.46%

The mean of analysts' price targets for Monte Rosa Therapeutics (GLUE) points to a 226.5% upside in the stock. While this highly sought-after metric h more_horizontal


Search within

Pages Search Results: